Retrospective Study to Capture Dosing & Treatment Outcome Data in

See also
Status	Clinical Trial	Phase
Completed	`NCT01127529` - Ceprotin Treatment Registry
Not yet recruiting	`NCT04180657` - Ghrelin Levels in Patients With Protein C Deficiency
Completed	`NCT00157118` - Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency	Phase 2/Phase 3

See also

Status

Clinical Trial

Phase

Completed

NCT01127529 - Ceprotin Treatment Registry

Not yet recruiting

NCT04180657 - Ghrelin Levels in Patients With Protein C Deficiency

Completed

NCT00157118 - Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency

Phase 2/Phase 3

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT00161720
Study type	Observational
Source	Takeda
Contact
Status	Completed
Phase
Start date	June 1, 2005
Completion date	December 1, 2005

Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms